Résumé
BACKGROUND: Currently, there are two difficult problems concerning amniotic fluid embolism. One is to find out the specific indicators for diagnosis of amniotic fluid embolism and the other is to prevent and treat amniotic fluid embolism. However, there are yet no effective treatments, and symptomatic treatment for clinical manifestations is the only treatment for amniotic fluid embolism, which has poor outcomes and leads to a high mortality rate. OBJECTIVE: To explore the feasibility of human amniotic mesenchymal stem cells to prevent and treat amniotic fluid embolism. METHODS: CNKI and PubMed data bases were searched for relevant articles with the key words of “amniotic fluid embolism, human amniotic mesenchymal stem cells" in Chinese and English, respectively. And finally 43 articles were included and summarized. RESULTS AND CONCLUSION: From the point of view of the pathogenesis of immune inflammatory reaction of amniotic fluid embolism, the immunology of pregnancy is related to transplantation biology. It is theoretically suggested that human amniotic mesenchymal stem cells can prevent and treat amniotic fluid embolism, regulate the immune system of the puerpera with amniotic fluid embolism, and reduce acute lung injury caused by amniotic fluid embolism. This method provides a new perspective for research on the prevention and treatment of amniotic fluid embolism.